Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2006-11-19
pubmed:abstractText
Receptor for advanced glycation end products (AGEs) (RAGE) plays a central role in the process of plaque rupture in diabetic patients. Recently, it has been reported that RAGE may be downregulated by improving glycemic control. In contrast, despite being well known that RAGE may be induced in human vessels in a glucose-independent fashion, also by myeloperoxidase (MPO)-dependent AGE generation, no data exist regarding the possibility of a pharmacological modulation of glucose-independent RAGE generation. Thus, the aim of this study was to characterize the effect of simvastatin on the expression of RAGE and RAGE-dependent plaque-destabilizing genes in human atherosclerotic plaques.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Anticholesteremic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase 2, http://linkedlifedata.com/resource/pubmed/chemical/Glucose, http://linkedlifedata.com/resource/pubmed/chemical/Glycosylation End Products, Advanced, http://linkedlifedata.com/resource/pubmed/chemical/Matrix Metalloproteinase 2, http://linkedlifedata.com/resource/pubmed/chemical/Matrix Metalloproteinase 9, http://linkedlifedata.com/resource/pubmed/chemical/Membrane Proteins, http://linkedlifedata.com/resource/pubmed/chemical/NF-kappa B, http://linkedlifedata.com/resource/pubmed/chemical/PTGS2 protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Peroxidase, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Immunologic, http://linkedlifedata.com/resource/pubmed/chemical/Simvastatin, http://linkedlifedata.com/resource/pubmed/chemical/advanced glycosylation end-product...
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1524-4636
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
26
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2716-23
pubmed:dateRevised
2007-7-25
pubmed:meshHeading
pubmed-meshheading:17038636-Aged, pubmed-meshheading:17038636-Anticholesteremic Agents, pubmed-meshheading:17038636-Carotid Stenosis, pubmed-meshheading:17038636-Cells, Cultured, pubmed-meshheading:17038636-Cyclooxygenase 2, pubmed-meshheading:17038636-Diabetes Mellitus, Type 2, pubmed-meshheading:17038636-Female, pubmed-meshheading:17038636-Gene Expression Regulation, pubmed-meshheading:17038636-Gene Expression Regulation, Enzymologic, pubmed-meshheading:17038636-Glucose, pubmed-meshheading:17038636-Glycosylation End Products, Advanced, pubmed-meshheading:17038636-Humans, pubmed-meshheading:17038636-Macrophages, pubmed-meshheading:17038636-Male, pubmed-meshheading:17038636-Matrix Metalloproteinase 2, pubmed-meshheading:17038636-Matrix Metalloproteinase 9, pubmed-meshheading:17038636-Membrane Proteins, pubmed-meshheading:17038636-NF-kappa B, pubmed-meshheading:17038636-Peroxidase, pubmed-meshheading:17038636-Receptors, Immunologic, pubmed-meshheading:17038636-Simvastatin
pubmed:year
2006
pubmed:articleTitle
Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes.
pubmed:affiliation
Atherosclerosis, Hypertension and Dyslipidemia Unit, G.d'Annunzio University of Chieti-Pescara, Italy.
pubmed:publicationType
Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't